▲ | text0404 4 days ago | ||||||||||||||||||||||
when you think of scientific research, do you imagine someone having an immediate eureka moment in a vacuum and writing a paper without having ever considered a problem before? do you understand that scientific progress takes years of dedication, hard work, trial and error, and then finally (occasionally) success? do you understand long-term survival and the necessity of planning for future generations, or are you just looking for the equivalent of this quarter's shareholder returns when it comes to advancing the species? | |||||||||||||||||||||||
▲ | infamouscow 4 days ago | parent [-] | ||||||||||||||||||||||
As a published researcher operating outside traditional academia, I find this rhetoric somewhat tiresome, as it overlooks the systemic interplay between public funding, academic training, and industrial commercialization in scientific advancement. To address your query on long-term planning for the species versus short-term gains, consider the role of tax dollars allocated through NSF grants to universities. These grants primarily support basic research and graduate education in fields like chemistry and biotechnology, which inherently trains the next generation of skilled workers for industry. For instance, the NSF Graduate Research Fellowship Program (GRFP) provides stipends and tuition support to outstanding graduate students pursuing research-based master's and doctoral degrees in STEM. Similarly, the NSF Research Traineeship (NRT) program funds interdisciplinary training for graduate students, often in areas such as chemical ecology or bio-inspired technologies, equipping them with advanced skills through hands-on research and stipends of at least 12 months. NSF accounts for approximately 25% of federal support for basic research at U.S. colleges and universities, much of which involves training students who subsequently enter the workforce. Most of these NSF-supported graduates are hired by multinational corporations in pharmaceuticals, biotechnology, and chemical manufacturing—entities like Pfizer, Moderna, or Dow Chemical, which are among the largest in history. Once in industry, these professionals conduct proprietary research behind closed doors to protect intellectual property and competitive advantages. The resulting products, novel drugs or biotechnological therapies, are frequently priced at astronomical levels, often rendering them unaffordable without insurance subsidies or government interventions. This raises serious questions about the equity of public investment: taxpayers fund the foundational training and basic discoveries, yet the downstream benefits accrue disproportionately to private shareholders through high-margin sales. In essence, while scientific progress indeed demands years of dedication, the current system subsidizes corporate profits via public education of the workforce. | |||||||||||||||||||||||
|